UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in Medtronic PLC (NYSE:MDT – Free Report) by 93.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 627,689 shares of the medical technology company’s stock after selling 9,106,059 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Medtronic were worth $49,104,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Anfield Capital Management LLC lifted its holdings in shares of Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 230 shares during the last quarter. Monetary Solutions Ltd purchased a new position in Medtronic during the 4th quarter valued at $27,000. Acumen Wealth Advisors LLC purchased a new stake in shares of Medtronic during the fourth quarter valued at $29,000. IAG Wealth Partners LLC purchased a new stake in Medtronic in the 2nd quarter valued at about $30,000. Finally, Imprint Wealth LLC bought a new position in Medtronic in the third quarter worth approximately $31,000. 82.06% of the stock is currently owned by institutional investors.
Medtronic News Roundup
Here are the key news stories impacting Medtronic this week:
- Positive Sentiment: Broad earnings beat and stronger outlook: Medtronic reported adjusted EPS of $1.45, above the $1.39 consensus, while revenue increased 13.7% year over year to $9.76 billion, exceeding estimates of $9.55 billion. Management raised fiscal 2027 organic revenue-growth guidance to 7.25%-7.75% and adjusted EPS guidance to $5.94-$6.00. Medtronic fiscal 2027 results
- Positive Sentiment: Growth was broad-based: Cardiovascular revenue rose 19.5%, neuroscience increased 10.3%, medical surgical grew 10.0% and diabetes advanced 16.9%. Analysts characterized the results as evidence of a potential growth acceleration across both established franchises and newer platforms. Medtronic beat-and-raise analysis
- Positive Sentiment: Robotics and heart-tech expansion: Medtronic committed approximately $700 million to a strategic partnership with Cornerstone Robotics, gaining distribution rights for its Sentire surgical system in select markets outside the United States. It also agreed to invest up to $80 million in Pi-Cardia to support complex TAVR procedures. These moves could broaden Medtronic’s long-term growth opportunities in minimally invasive surgery and structural heart care. Cornerstone Robotics partnership
- Positive Sentiment: Analyst support increased: RBC reaffirmed an Outperform rating and set a $118 price target. BTIG raised its target to $100 and maintained a Buy rating, while Baird lifted its target to $100. These revisions indicate improving confidence in Medtronic’s earnings trajectory. Analyst price-target revisions
- Neutral Sentiment: Some caution remains: Stifel raised its price target to $95 but kept a Hold rating, and Baird retained a Neutral rating despite its higher target. The second-quarter EPS outlook of $1.32-$1.34 is below the $1.35 consensus, suggesting investors may continue to watch execution and the sustainability of the recent growth acceleration.
Medtronic Trading Up 0.1%
Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.89% and a net margin of 13.93%.The company had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. During the same quarter last year, the firm posted $1.26 EPS. The firm’s revenue for the quarter was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, sell-side analysts anticipate that Medtronic PLC will post 5.96 EPS for the current fiscal year.
Medtronic Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a $0.72 dividend. The ex-dividend date is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.1%. Medtronic’s dividend payout ratio is 70.94%.
Analyst Upgrades and Downgrades
MDT has been the topic of a number of recent research reports. Rothschild & Co Redburn dropped their price objective on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating on the stock in a research note on Friday, June 5th. UBS Group upgraded Medtronic from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $85.00 to $100.00 in a research note on Tuesday, July 28th. Jefferies Financial Group reissued a “hold” rating and set a $88.00 price objective on shares of Medtronic in a report on Thursday, June 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Medtronic in a report on Tuesday, August 18th. Finally, Truist Financial reaffirmed a “hold” rating and set a $99.00 price target (up from $86.00) on shares of Medtronic in a research report on Wednesday. Nineteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and a consensus price target of $102.96.
View Our Latest Stock Report on Medtronic
Insider Transactions at Medtronic
In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the sale, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This trade represents a 10.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.27% of the stock is currently owned by insiders.
About Medtronic
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Featured Articles
- Five stocks we like better than Medtronic
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
